Trial Profile
A Randomised Phase II Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma (RRMM) Patients Who Have Relapsed After Treatment With Thalidomide, Lenalidomide and Bortezomib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2022
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms MUK Eight
- 04 Apr 2022 Status changed from active, no longer recruiting to completed.
- 02 Oct 2020 Trial design, published in the Trials
- 21 Jan 2020 Planned End Date changed from 1 May 2019 to 1 Jan 2021.